TC Biopharm (Holdings) Plc (TCBPY)
| Market Cap | 86.18K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -14.63M |
| Shares Out | 410.39K |
| EPS (ttm) | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,082 |
| Average Volume | 941,275 |
| Open | 0.2100 |
| Previous Close | 0.2100 |
| Day's Range | 0.1800 - 0.3750 |
| 52-Week Range | 0.1600 - 523.2000 |
| Beta | 0.52 |
| RSI | n/a |
| Earnings Date | Apr 2, 2025 |
About TC Biopharm (Holdings)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. [Read more]
News
TCBP Announces Transition from Nasdaq to OTC Markets
EDINBURGH, Scotland , March 21, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company"), (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic g...
TCBP Announces Outsourcing Initiatives, Reducing Burn Rate and Overhead
The company is expected to reduce core operational burn by 55% when compared to 2024 EDINBURGH, Scotland , March 18, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (N...
TCBP Announces Non-Binding Letter of Intent to Acquire Commercial Stage Ophthalmic Pharmaceutical Company
FDA-approved product in a multi-billion-dollar market Revenue generation projected in 2025 EDINBURGH, Scotland , March 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company...
TCBP CEO Bryan Kobel to Participate on Cancer Progress Panel at 18th Annual European Life Sciences CEO Forum
EDINBURGH, Scotland , Feb. 20, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) , a clinical-stage biotechnology company developing platform allogeneic g...
TCBP Announces Successful Completion of Cohort A in the ACHIEVE Clinical Trial
No adverse events related to TCB008 have occurred Evidence of stable disease following TCB008 infusion EDINBURGH, Scotland , Feb. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or ...
TCBP Announces Successful Completion of Initial Cohort B Patient Dosing in the ACHIEVE Clinical Trial
First Cohort B patient received 4 doses (approx. 819 million Gamma Delta T-cells) Cohort B recruitment continues at multiple clinical sites across the United Kingdom EDINBURGH, Scotland , Feb. 10, 202...
TCBP to Implement ADS Ratio Change
EDINBURGH, Scotland , Feb. 5, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamm...
TCBP Announces H5N1 Proof of Concept Studies Intention
EDINBURGH, Scotland , Jan. 15, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gam...
TCBP to Present at Sequire Investor Summit 2025
EDINBURGH, Scotland , Jan. 13, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic ga...
TCBP Trading Continues Unabated on Nasdaq Stock Exchange
EDINBURGH, Scotland , Jan. 6, 2025 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamm...
TCBP Provides Update on Acquisition Strategy and Current Targets
EDINBURGH, Scotland , Dec. 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gam...
TCBP Issues 25% Stock Dividend
EDINBURGH, Scotland , Dec. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gam...
TCBP Advances ACHIEVE Phase 2b Clinical Trial with Final Dosing of 3 Patients
EDINBURGH, Scotland , Dec. 20, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gam...
TCBP Announces General Meeting of Shareholders to Approve One-Time Shareholder Dividend
EDINBURGH, Scotland , Dec. 18, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gam...
EXCLUSIVE: Penny Stock TC BioPharm Proposes Special Stock Dividend
On Wednesday, TC BioPharm (Holdings) PLC TCBP announced that its Board of Directors approved a special dividend of 0.25 American Depositary Shares for every 1 ADS held by shareholders, pending shareho...
TCBP Partners with CareDx to Support ACHIEVE Clinical Trial Using AlloCell for Pharmacokinetic Monitoring of Allogeneic Cell Therapy
EDINBURGH, Scotland , Dec. 11, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gam...
TCBP Provides Quarterly Update on the ACHIEVE (UK) Clinical Trial
Positive safety data, allowing for exploration of higher TCB008 doses 4 UK-based clinical sites recruiting patients, with a further 2 sites expected in H1 2025 EDINBURGH, Scotland , Dec. 4, 2024 /PRNe...
TCBP Awarded Non-Dilutive Funding, ScaleReady's G-Rex® Grant
EDINBURGH, Scotland , Nov. 12, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic ga...
TCBP Provides Shareholder Update and Highlights Recent Milestone Achievements
EDINBURGH, Scotland , Oct. 30, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic ga...
TCBP Responds to False Social Media Claim
TC BioPharm remains compliant with all Nasdaq listing requirements and will continue trading on the exchange EDINBURGH, Scotland , Oct. 25, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPhar...
TCBP Enters Research Planning Collaboration with Dr. Carlos Maluquer de Motes for Mpox Therapeutic
EDINBURGH, Scotland , Oct. 22, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP), a clinical-stage biotechnology company developing platform allogeneic ga...
TCBP Announces Artificial Intelligence Initiative with Partner Carnegie Mellon University for Donor Screening
TC BioPharm Limited is partnering with Dr. Wei Wu of Carnegie Mellon University to create an artificial intelligence solution to optimize the donor screening and matching process The software could ha...
TCBP Announces Site Opening of Guys and St. Thomas Hospital
Additional London-based clinic to increase enrolment velocity Leading hospital with extensive cell therapy and oncology trial experience EDINBURGH, Scotland , Sept. 25, 2024 /PRNewswire/ -- TC BioPhar...
TCBP to Present at the 2024 ThinkEquity Conference in NYC
EDINBURGH, Scotland , Sept. 24, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic ga...
TCBP Announces First Patient Completed the Full Fose Regimen in ACHIEVE Clinical Trial
No TCB008-related Adverse Events seen in any of the re-start patients 6 Patients received second dose, 3 Patients received third dose, 1 Patient received fourth dose EDINBURGH, Scotland, Sept. 12, 202...